A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy

计划入组 20 人 · 首次发布于 2025 年 11 月 13 日

Phenylbutyrate for Monogenetic Developmental and Epileptic Encephalopathy

计划入组 50 人 · 首次发布于 2021 年 6 月 23 日

XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy

计划入组 8 人 · 首次发布于 2020 年 11 月 20 日

Developmental and epileptic encephalopathy (Biogen)

STXB1 gene therapy (AAV, developmental and epileptic encephalopathy)

WWOX gene (spinocerebellar ataxia 12/developmental and epileptic encephalopathy)

Alzheimer's Disease And Related Disorders Association, Inc.

United States

Alzheimer's Disease And Related Disorders Association, Georgia Chapter, Inc.

United States

BROOKDALE UNIVERSITY HOSPITAL MEDICAL CENTER

United States

Servier Enrolls First Patient in Phase Ib/II Trial of ASO Therapy for KCNT1-Related Pediatric Epilepsy

CAP-002 Receives FDA Orphan Drug Designation for STXBP1-Related Developmental and Epileptic Encephalopathy

Actio Biosciences Receives FDA Clearance and Fast Track Designation for First-in-Class KCNT1 Epilepsy Treatment